Delcath Systems, Inc. (DCTH)
| Market Cap | 36.05M |
| Revenue (ttm) | 3.54M |
| Net Income (ttm) | -27.11M |
| Shares Out | 7.91M |
| EPS (ttm) | -3.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,521 |
| Open | 4.61 |
| Previous Close | 4.50 |
| Day's Range | 4.40 - 4.78 |
| 52-Week Range | 4.30 - 13.50 |
| Beta | 0.55 |
| Analysts | Buy |
| Price Target | 22.44 (+392.1%) |
| Earnings Date | May 10, 2022 |
About DCTH
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rat...
Financial Performance
In 2021, DCTH's revenue was $3.56 million, an increase of 115.98% compared to the previous year's $1.65 million. Losses were -$25.65 million, 6.18% more than in 2020.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for DCTH stock is "Buy." The 12-month stock price forecast is 22.44, which is an increase of 392.11% from the latest price.
News
Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates
Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of -19.05% and 70%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Delcath Systems Reports First Quarter 2022 Results and Provides Business Update
NEW YORK , May 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today report...
Delcath Announces Poster Presentation at the 2022 ASCO Annual Meeting
NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announc...
Delcath Systems to Host First Quarter 2022 Results
NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced t...
Delcath Systems to Participate in the Canaccord Genuity Horizons in Oncology Conference
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will partic...
Delcath Systems to Participate in the Lytham Partners Spring 2022 Investor Conference
NEW YORK, March 29, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced t...
Delcath Systems, Inc. (DCTH) Reports Q4 Loss, Tops Revenue Estimates
Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of 25.81% and 285.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Delcath Systems Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update
NEW YORK, March 25, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today repor...
Delcath Systems to Host Fourth Quarter and Full Year 2021 Results
NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced t...
Delcath Systems Achieves Medical Device Regulation Certification for CHEMOSAT® in Europe
NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased ...
Delcath Systems Announces Move to a Direct Sales & Marketing Model for CHEMOSAT®
NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced to...
Delcath Systems to Present at Upcoming Virtual Investor Conferences
NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced to...
Delcath Appoints Anthony Dias as its new Vice President of Finance; Inducement Grant Reported
NEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced to...
Delcath's Chemosat Hepatic Delivery System Shows Overall Response Rate Of 60.5% In Eye Cancer That Spreads To Liver
Delcath Systems Inc's DCTH single-institution retrospective study data on CHEMOSAT Hepatic Delivery System for liver dominant metastatic uveal melanoma (mUM) were published in the journal Melanoma Rese...
Results of Single Center Study on Delcath's CHEMOSAT® Hepatic Delivery System Published in Melanoma Research
Retrospective Study by University Hospital Southampton in metastatic uveal melanoma (mUM) patients with liver dominant disease shows hepatic disease control rate of 88.9%, hepatic response rate of 66.7%...
David Hoffman Joins Delcath Systems, Inc. as General Counsel and Corporate Secretary
NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announ...
Delcath Systems to Present at the H.C. Wainwright BioConnect Virtual Investor Conference on January 10, 2022
NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced to...
Delcath Systems Reveals Initial Survival Data From Ocular Melanoma Trial
Delcath Systems Inc (NASDAQ: DCTH) has announced results from the Phase 3 FOCUS study of Hepzato Kit (melphalan hydrochloride for injection/hepatic delivery system) in patients with liver dominant metas...
Delcath Systems, Inc. (DCTH) Reports Q3 Loss, Misses Revenue Estimates
Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of -3.30% and -9.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Delcath Systems Q3 Earnings
Delcath Systems (NASDAQ:DCTH) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the announcement.
Delcath Systems Announces Third Quarter 2021 Results
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today r...
Delcath Systems, Inc. (DCTH) Stock Jumps 6.6%: Will It Continue to Soar?
Delcath Systems, Inc. (DCTH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...
Delcath Systems to Participate in the Canaccord Virtual MedTech, Diagnostics and Digital Health & Services Forum on N...
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announ...
Delcath Systems to Hold Investor Update on Focus Trial Data and Future Development Plans on December 2, 2021
NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced t...
Will Delcath Systems, Inc. (DCTH) Report Negative Earnings Next Week? What You Should Know
Delcath Systems, Inc. (DCTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.